Rechercher
image du produit
Biomedicine and pharmacotherapy

S'abonner

Recent advances in the therapeutic potential of emodin for human health - 10/09/22

Doi : 10.1016/j.biopha.2022.113555 
Javad Sharifi-Rad a, ⁎ , Jesús Herrera-Bravo b, c, Senem Kamiloglu d, e, Katia Petroni f , Abhay Prakash Mishra g , Margalida Monserrat-Mesquida h, i , Antoni Sureda h, i, ⁎ , Miquel Martorell b, j, ⁎ , Dossymbetova Symbat Aidarbekovna k , Zura Yessimsiitova l , Alibek Ydyrys m , Christophe Hano n, ⁎ , Daniela Calina o, ⁎ , William C. Cho p, ⁎
a Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador 
b Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Chile 
c Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811230, Chile 
d Department of Food Engineering, Faculty of Agriculture, Bursa Uludag University, 16059 Gorukle, Bursa, Turkey 
e Science and Technology Application and Research Center (BITUAM), Bursa Uludag University, 16059 Gorukle, Bursa, Turkey 
f Dipartimento di Bioscienze, Università degli Studi di Milano, via Celoria 26, 20133 Milano, Italy 
g Department of Pharmaceutical Chemistry, H.N.B. Garhwal (A Central) University, Srinagar Garhwal, Uttarakhand 246174, India 
h Research Group in Community Nutrition and Oxidative Stress, University Research Institute of Health and Health Research Institute of Balearic Islands (IdISBa), University of the Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain 
i CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain 
j Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepción, 4070386 Concepción, Chile 
k Almaty Tecnological University, Kazakh-Russian Medical University, Almaty 050012, str. Tole bi 100, Str. Torekulova 71, Kazakhstan 
l Department of Biodiversity and Bioresource, Al-Farabi Kazakh National University, al-Farabi av. 71, 050040 Almaty, Kazakhstan 
m Biomedical Research Centre, Al-Farabi Kazakh National University, al-Farabi av. 71, 050040 Almaty, Kazakhstan 
n Department of Biological Chemistry, University of Orleans, Eure et Loir Campus, 28000 Chartres, France 
o Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 
p Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong 

⁎Corresponding authors.⁎⁎Corresponding author at: Research Group in Community Nutrition and Oxidative Stress, University Research Institute of Health and Health Research Institute of Balearic Islands (IdISBa), University of the Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain.Research Group in Community Nutrition and Oxidative Stress, University Research Institute of Health and Health Research Institute of Balearic Islands (IdISBa), University of the Balearic Islands-IUNICSPalma de Mallorca07122Spain⁎⁎⁎Corresponding author at: Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepción, 4070386 Concepción, Chile.Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of ConcepciónConcepción4070386Chile

Abstract

Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is a bioactive compound, a natural anthraquinone aglycone, present mainly in herbaceous species of the families Fabaceae, Polygonaceae and Rhamnaceae, with a physiological role in protection against abiotic stress in vegetative tissues. Emodin is mainly used in traditional Chinese medicine to treat sore throats, carbuncles, sores, blood stasis, and damp-heat jaundice. Pharmacological research in the last decade has revealed other potential therapeutic applications such as anticancer, neuroprotective, antidiabetic, antioxidant and anti-inflammatory.

The present study aimed to summarize recent studies on bioavailability, preclinical pharmacological effects with evidence of molecular mechanisms, clinical trials and clinical pitfalls, respectively the therapeutic limitations of emodin. For this purpose, extensive searches were performed using the PubMed/Medline, Scopus, Google scholar, TRIP database, Springer link, Wiley and SciFinder databases as a search engines. The in vitro and in vivo studies included in this updated review highlighted the signaling pathways and molecular mechanisms of emodin. Because its bioavailability is low, there are limitations in clinical therapeutic use. In conclusion, for an increase in pharmacotherapeutic efficacy, future studies with carrier molecules to the target, thus opening up new therapeutic perspectives.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




ga1

Le texte complet de cet article est disponible en PDF.

Highlights

•
Emodin is an anthraquinone used since ancient times in traditional Chinese medicine.
•
It has therapeutic effects in cancer, diabetes, neurodegenerative diseases or chronic inflammatory diseases.
•
This paper presents updated molecular mechanisms of action and signaling pathways of emodin.
•
Additional human clinical trials to confirm its efficacy and safety are needed.

Le texte complet de cet article est disponible en PDF.

Keywords : Emodin, Pharmacological properties, Molecular mechanisms, Signaling pathways, Clinical trials


Plan


© 2022  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

    •

  • Contenu

    •

Vol 154

Article 113555- octobre 2022 Retour au numéro
Article précédent Article précédent
  • Anti-Alzheimer's disease potential of traditional chinese medicinal herbs as inhibitors of BACE1 and AChE enzymes
  • Renhui Dai, Yingni Sun, Ruiling Su, Hongwei Gao
| Article suivant Article suivant
  • The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms
  • Vali Musazadeh, Arash Karimi, Nasim bagheri, Jaber Jafarzadeh, Sarvin Sanaie, Mahdi Vajdi, Mozhde Karimi, Hamid Reza Niazkar

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.